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Abstract
Background: Little is known about the parasite/host factors that lead to Post Kala-azar Dermal Leishmaniasis (PKDL)
in some visceral leishmaniasis (VL) patients after drug-cure. Studies in Sudan provide evidence for association
between polymorphisms in the gene (IFNGR1) encoding the alpha chain of interferon-γ receptor type I and risk
of PKDL. This study aimed to identify putative functional polymorphisms in the IFNGR1 gene, and to determine
whether differences in expression of interferon-γ (IFNG) and IFNGR1 at the RNA level are associated with pathogenesis
of VL and/or PKDL in Sudan.
Methods: Sanger sequencing was used to re-sequence 841 bp of upstream, exon1 and intron1 of the IFNGR1 gene in
DNA from 30 PKDL patients. LAGAN and SYNPLOT bioinformatics tools were used to compare human, chimpanzee
and dog sequences to identify conserved noncoding sequences carrying putative regulatory elements. The relative
expression of IFNG and IFNGR1 in paired pre- and post-treatment RNA samples from the lymph nodes of 24 VL
patients, and in RNA samples from skin biopsies of 19 PKDL patients, was measured using real time PCR. Pre- versus
post-treatment expression was evaluated statistically using the nonparametric Wilcoxon matched pairs signed-rank test.
Results: Ten variants were identified in the 841 bp of sequence, four of which are novel polymorphisms at -77A/G, +10
C/T, +18C/T and +91G/T relative to the IFNGR1 initiation site. A cluster of conserved non-coding sequences with
putative regulatory variants was identified in the distal promoter of IFNGR1. Variable expression of IFNG was
detected in lymph node aspirates of VL patients before treatment, with a marked reduction (P = 0.006) in expression
following treatment. IFNGR1 expression was also variable in lymph node aspirates from VL patients, with no significant
reduction in expression with treatment. IFNG expression was undetectable in the skin biopsies of PKDL cases, while
IFNGR1 expression was also uniformly low.
Conclusions: Uniformly low expression of IFN and IFNGR1 in PKDL skin biopsies could explain parasite persistence
and is consistent with prior demonstration of genetic association with IFNGR1 polymorphisms. Identification of novel
potentially functional rare variants at IFNGR1 makes an important general contribution to knowledge of rare variants of
potential relevance in this Sudanese population.
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Background
Post Kala-azar Dermal Leishmaniasis (PKDL) is a compli-
cation of treatment for patients with visceral leishmaniasis
(VL) caused by Leishmania donovani and results in the
presence of multiple hypopigmented papules or nodules
on the skin. PKDL patients are considered a potential res-
ervoir for anthroponotic leishmaniasis owing to the high
number of parasites in their skin [1,2]. Taking into consid-
eration the high incidence of PKDL cases in East Africa,
and the ability to experimentally infect P. orientalis fed
on VL patients, Elnaiem and colleagues [3] concluded
that transmission from human to human is common.
Although it has been suggested that immune suppres-
sion may occur in PKDL patients, allowing renewed
multiplication of latent parasites from the viscera or re-
infection of the skin, the pathogenesis of disease remains
unclear [4]. According to studies conducted in Sudan,
reactivation of leishmania-specific lymphocyte is con-
sidered to be the major underlying mechanism in PKDL
development [5]. Inadequate treatment, host genetics, and
immune response may all play a role in the development
of PKDL.
Susceptibility or resistance to leishmaniasis shows
marked variation within and between genetically diverse
human populations. Genetic analyses of VL in the
Sudanese population revealed that PKDL induced by
L. donovani infection is influenced by polymorphisms
in the gene, IFNGR1, encoding the receptor α-chain for
interferon-γ [6,7]. Failure of macrophages to become
activated to kill parasites during PKDL may be due to
low expression of IFNGR1 which may lead to a gap in
downstream signalling [8,9].
Transcriptional regulation is considered to be an im-
portant step in gene regulation because it controls the
number of copies of primary transcripts, which is the first
type of biomolecule produced during the gene expression
process. Several IFNGR1 polymorphisms/mutations were
identified in patients with different diseases. Sequence
analysis of 2.5 kb spanning the promoter region to exon1
of the IFNGR1 gene in 24 Japanese individuals, 12 un-
affected and 12 atopic dermatitis patients, identified nine
polymorphisms, five of which were detected in the pro-
moter region while the other four variants were found in
exon 1 [10]. The -56C/T promoter polymorphism, where
the T allele was associated with higher IFNGR1 tran-
scriptional activity, represented a genetic risk factor
for ocular complications of atopic dermatitis [10]. Koch
and co-workers [11] sequenced 1400 bp upstream of the
transcriptional start site in 34 randomly selected Gambian
umbilical cord blood samples and 36 Gambian tubercu-
losis (TB) patients. They identified four polymor-
phisms, -470delTT, -270 T/C, -56C/T, and +95 T/C.
Genotyping these polymorphisms in cord blood con-
trols and severe malaria patients showed that individuals
carrying the double deletion at -470delTT were protected
against severe malaria in the Mandinka ethnic group, while
heterozygosity at the -56C/T SNP was specifically associ-
ated with protection from cerebral malaria [11]. Awomoyi
and co-workers [12] sequenced a further 32 patients with
pulmonary TB from The Gambia, but reported no further
novel variants and found no disease associations for TB
when comparing 320 smear positive TB cases with 320
matched controls. Polymorphism at the -56 T/C SNP is
associated with the clinical outcome of HBV infection in
Chinese adults, with the C allele associated with viral clear-
ance and the T allele associated with viral persistence [13].
In Sudan, we found that risk of PKDL was associ-
ated with the T allele at the -270 T/C polymorphism,
but not with the three polymorphisms -470delTT, -56C/T,
or +95 T/C individually [7]. Nevertheless, global associ-
ation with haplotypes comprising all four markers at
IFNGR1 was observed, associated with a significant bias in
transmission of the (-470 bp_-270 bp_-56 bp_ + 95 bp)
haplotype insTT_T_T_T and less than expected transmis-
sion of insTT_C_C_C. When compared with data on mal-
aria associations from The Gambia, the results suggested
a complex pattern of haplotypic variation at the IFNGR1
promoter locus associated with different infectious disease
in African populations, prompting us to explore further
the possibility of additional promoter region polymor-
phisms in the Sudanese population. This study was there-
fore carried out to determine whether novel and putative
functional variants occur in regulatory regions of the
IFNGR1 locus in Sudanese individuals, and to determine
whether differences in expression of IFNG and IFNGR1 at
the RNA level are associated with pathogenesis of VL
and/or PKDL in an endemic region of Sudan.
Methods
Study subjects
Lymph node aspirates from 24 paired pre- and post-
treatment (sodium stibogluconate, 20 mg/kg/day for
30 days) VL patients (14 males, 10 females; age range 5 to
30 years), and 19 skin biopsies from PKDL patients (12
males, 7 females; age range 5 to 30 years), were collected in
5× RNA later (AMBioN Inc., Austin, texas, USA) and kept
at −20°C until RNA was isolated. Normal skin tissue RNA
(STRATAGENE, Foster City CA, USA) was included as
control. Peripheral blood mononuclear cells (PBMCs) from
blood samples of an additional 30 PKDL patients (19 males,
11 females; age range 5 to 30 years) were collected in trans-
port buffer and stored at 4°C until DNA was extracted. The
patients were recruited from Kassab Hospital–Elgadarif
state, Sudan, during 2008 and 2009. Fever, hepatomegaly,
splenomegaly, anaemia, leukopenia and hypo-albuminemia
were observed in most VL patients. Diagnosis was carried
out microscopically by demonstration of Leishmania amas-
tigotes from either lymph node or bone marrow aspirates.
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Ethical considerations
The study was approved by the Institutional Review Board
known as the Ethics Committee of Institute of Endemic
Diseases, University of Khartoum. Written informed con-
sent was obtained from all adult participants, and from
the parent or guardian where participants were less than
18 years old. All clinical investigations were conducted




Genomic DNA was extracted from PBMCs using DNeasy
Blood & Tissue Kit in accordance with the manufacturer’s
instruction (QIAGEN). The 1029 bp genomic region of
the IFNGR1 gene targeted for sequencing included 841 bp
of upstream sequence, plus exon1 and intron1 (Ensembl
v73; http://browser.1000genomes.org). This target region
was amplified from 30 PKDL DNA samples using primers:
5′AAACAGTAGGGCGGGGTAAG3′ and 5′AAATCAA
ATCGGCTTGACCA3′ designed using primer 3 software
(http://frodo.wi.mit.edu/primer3/). Sanger sequencing re-
actions were outsourced to the Macrogen Company, Seoul,
South Korea.
Real time PCR
Total RNA was isolated from paired lymph node sam-
ples for the 24 pre- and post-treatment VL patients, and
from skin biopsies for the PKDL patients using the
RNeasy Micro kit (Qiagen, GmbH, Hilden, Germany) ac-
cording to the manufacturer’s instruction. Sample quality
and integrity was assessed by NanoDrop spectrophotom-
eter (ND-1000). Complementary DNA (cDNA) was synthe-
sized using MMLV reverse transcriptase kit (Stratagene)
in accordance with the manufacturer’s instruction. The
SYBER Green gene expression assay (2× Brilliant SYBER
Green QPCR master mixes, STRATAGENE) was used
to measure expression (MX3000P Real Time PCR sys-
tem, STRATAGENE, Foster City CA, USA) of IFNG and
IFNGR1, with β-Actin used as an endogenous control.
Sense and antisense primers for IFNG, IFNGR1 and
β-Actin were designed using primer 3 software (http://
frodo.wi.mit.edu/primer3/) (Table 1). Controls without tem-
plate were included in each plate. All samples were run in
duplicate. Expression of target genes was normalized to
endogenous control using the standard curve method for
relative quantitation according to Stratagene’s instructions.
Final results for PKDL samples are shown relative to
the control skin tissue RNA. Results were analysed in
GraphPad Prism (version 5.00 for Windows, Graph Pad
Software, San Diego California USA, http://www.graphpad.
com). Statistical differences between VL pre- and post-
treatment groups were determined using the nonpara-
metric Wilcoxon matched pairs signed-rank test.
Bioinformatics analysis
Polymorphisms within the 841 bp fragment amplified
upstream and across exon1 and intron1 of IFNGR1 were
identified using the BioEdit program (http://www.mbio.
ncsu.edu/BioEdit/bioedit.html) [14]. Linkage disequilib-
rium between polymorphic variants was determined using
Haploview v4.2 [15] (http://sourceforge.net/projects/
haploview/). To identify regulatory polymorphisms within
conserved non coding sequences (CNSs) upstream of
the IFNGR1 gene, a 3.5 kb region of genomic sequences
and associated gene annotations for human, chimpanzee,
and dog were exported from Ensembl (National Center
for Biotechnology Information build 36; Ensembl release
73) in FASTA and General Feature File (GFF) formats, re-
spectively. Global alignment of genomic sequences was
performed in Multi-LAGAN (http://lagan.stanford.edu/
lagan_web/index.shtml) [16,17]. The annotated alignment
was visualized in SynPlot (http://hscl.cimr.cam.ac.uk/syn_
plot.html), and CNSs of a specified percentage were identified
in SynPlot-Peaks (http://hscl.cimr.cam.ac.uk/syn_plot_
peaks.html) [18]. To search for putative transcription
factor binding sites (TFBSs) at SNP locations, the online
software tools AliBaba [19] (version 2.1; http://www.gene-
regulation.com/pub/programs.html) and MatInspector [20]
((Genomatix) Matrix Family Library Version 9.1) were used.
Results
Sequence analysis of IFNGR1
Associations between PKDL and functional polymorphisms
in the IFNGR1 promoter region [7] encouraged us to screen
for additional SNPs or other variants within potential regu-
latory regions of the IFNGR1gene. Sequencing of 841 bp
upstream, exon1 and intron1 of IFNGR1 in 30 DNA from
PKDL patients revealed ten genetic variants (Table 2).
Four of these were not previously reported in public do-
main DNA databases (Ensembl v73; http://browser.1000
genomes.org): IFNGR1 -77A/G in the 5‴ promoter re-
gion, IFNGR1 + 10C/T and IFNGR1 + 18C/T in exon1,
and IFNGR1 + 91G/T in intron1. The +10 C/T poly-
morphism in exon1 of IFNGR1 resulted in an amino acid
change from Leucine (L) to Phenylalanine (F), which lies
in the same class (Non Polar). No change in amino acid
Table 1 Sense and anti-sense sequences for the
housekeeping gene and cytokines
Gene Primer sequence Product
size (bp)
B-Actin Fwd. 5′CTGTGGCATCCACGAAACTA 3′ 200
Rev. 5′AGTACTTGCGCTCAGGAGGA 3′
IFNG Fwd. 5′GTTTTGGGTTCTCTTGGCTGTTA 3′ 113
Rev. 5′AAAAGAGTTCCATTATCCGCTACATC 3′
IFNGR1 Fwd. 5′GCCACAGGTCCCTGTTTTTA 3′ 163
Rev. 5′TCCAACCCTGGCTTTAACTC 3′
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was associated with the +18C/T polymorphism. Substitu-
tion from A to G at the IFNGR1 -77 bp polymorphism re-
sulted in loss of the transcription factor binding sites
for cAMP response element-binding (CREB) and hypoxia
response element (HRE). Only the +91G/T polymorphism
has a minor allele frequency >0.1 (Table 2). As such, it is
the only novel polymorphism that could provide sufficient
power to contribute to risk versus protective haplotypes
that might account for the association with PKDL in
this population. However, due to the low minor allele
frequencies, strong linkage disequilibrium was only
detected between the known SNPs IFNGR1 + 95 T/C and
IFNGR1 -56 T/C (r2 = 0.71), in broad agreement with link-
age disequilibrium between these two SNPs in the Yoruba
(YRI) (r2 = 1), European (CEU) (r2 = 1), Japanese (JPN)
(r2 = 1), and Han Chinese in Beijing (HCB) (r2 = 1) HapMap
populations. Of interest, the novel SNP at +91 bp was
not in strong linkage disequilibrium with the known
SNPs as -56 bp (r2 = 0.01) or at +95 bp (r2 = 0.08). There-
fore we conclude that it does not contribute to the
association with PKDL previously observed for haplotypes
involving these two markers [7].
Bioinformatics analysis for conserved non-coding
sequences (CNSs)
Sequencing of the immediate promoter region identified
4 novel variants in the Sudanese population. However,
minor allele frequencies were low making it unlikely that
these variants contributed on their own to risk and pro-
tective haplotypes for PKDL. Therefore in silico methods
were employed to interrogate an extended region up to
3.5 kb upstream of the initiation start site of the IFNGR1
gene. The strategy was to: (i) identify regions of conserved
sequence (CNS) that are more likely to carry regulatory el-
ements; (ii) identify TFBS within these CNS using predict-
ive software tools; and (iii) determine whether known
SNPs located within CNS cause loss or gain of relevant
transcription factor binding activity. To identify CNSs,
comparative sequence analysis was performed between
human, chimpanzee, and dog for ~3.5 kb upstream re-
gion of IFNGR1 gene. A number of CNSs were identified
across the region based on the criteria of 70% similarity
over at least 100 bp of ungapped alignment [21,22].
Within this region we identified 3 CNSs in the inter-
genic region upstream of the IFNGR1 gene (Figure 1)
which we interrogated for public domain SNP informa-
tion. In total we found information on 21 SNPs across the
3.5 kb regions upstream of the IFNGR1 initiation site, 13
of which fell within CNSs as annotated on Figure 1. No
known SNPs were located within peak 1. Seven SNPs were
identified in peaks 2 and 3, as presented in Table 3. Two
out of the ten SNPs that were detected in the sequence
analysis (Table 2) are located within the CNS labelled peak
4 which encompasses the 5′UTR (Figure 1). IFNGR1
rs41401746 (−470 bp TT/– INDEL) upstream of IFNGR1
is positioned within peak 4, which showed 81% identity
over 182 nucleotides across human, chimpanzee, and dog
sequences. The rs141836145 (−270 bp T/C) SNP, which
was found to be associated with PKDL in our previous
study [7], is also located within peak 4. Four known SNPs
(rs55961762, rs55640745, rs56300633, and rs17181653),
also located within peak 4, were not polymorphic in the
30 PKDL samples that were sequenced (data not shown).
Seven known SNPs in the SNPDB database fall within
CNS peaks 2 and 3 located within the region 1000-
2800 bp region upstream of IFNGR1 (Table 3). Six of
them, rs55995532, rs17175064, rs1327473, rs56273545,
rs56178591, and rs17175057, are located within peak 3
which shows 79% identity across species over 154 nu-
cleotides of alignment. The seventh SNP, rs17175050,
is located within peak 2 which shows 81% identity across
species over 365 nucleotides of alignment. Carriage of
alternative alleles at rs55995532, rs1327473, and rs17175050,
rs56178591, rs17175057 result in loss or gain of transcription
Table 2 List of IFNGR1 SNPS detected in Sudanese PKDL patients
SNP Region Alleles Position Consequence (Loss or gain TFBSa, AA change, splicing site) MAFb
rs1327474 5′-Promoter A/G −611 HOXC13, GATA 0.057
rs41401746 5′-Promoter TT/– −470 PU.1, Lyf-1 0.020
rs14183614 5′-Promoter T/C −270 - 0.017
rs7753590 5′-Promoter T/G −187 SP1, EKLF 0.035
Novel 5′-Promoter A/G −77 CREB, HRE 0.013
rs2234711 5′-Promoter T/C −56 MIZ1 0.476
Novel Exon 1 C/T +10 Leu/Phe 0.012
Novel Exon 1 C/T +18 Synonymous 0.023
Novel Intron 1 G/T +91 Splicing site 0.108
rs7749390 Intron 1 T/C +95 Splicing site 0.388
aTFBS, transcription factor binding site; grey shading, loss of TFBS; italics, gain of TFBS; AA = Amino Acid; bMAF =minor allele frequency. Bold indicates novel
variants found in this study.
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factor binding sites for C/EBPbeta, AP-1, NF-1/GATA-1/
ZBTB3, MAZ/ ZNF263, and SP1/ KLF7, respectively
(Table 3). However, public domain minor allele frequency
information (Table 3) indicates that, as for the novel SNPs
identified in the re-sequencing analysis, these SNPs are
either known to be rare variants or likely to be in the
situation where no allele frequency data is available in
SNPDB.
Expression of IFNG and IFNGR1 at the RNA level
To understand more about the possible role of IFNG and
IFNGR1 genes in the development of PKDL, their expres-
sion relative to an endogenous house-keeping gene was
measured in RNA samples prepared from paired pre- and
post-treatment lymph node aspirates from VL patients,
and from skin biopsies from PKDL patients. Variable ex-
pression of IFNG was detected in lymph node aspirates of
VL patients before treatment (Figure 2A), with a marked
reduction (P = 0.006) in expression following treatment in
paired pre- versus post-treatment samples. IFNGR1 ex-
pression was also variable in lymph node aspirates from
VL patients, with no significant change in expression with
treatment measured in paired pre- versus post-treatment
samples. IFNG expression was undetectable in the skin bi-
opsies of PKDL cases (Figure 2B), as it was in the normal
commercial control skin. IFNGR1 expression was detect-
able but also uniformly low, especially relative to levels
observed in the lymph nodes of VL patients.
Discussion
IFNGR1 gene polymorphisms were shown to be linked
and associated specifically with PKDL in Sudan [6,7]. To
determine whether additional polymorphisms influence
the development of this neglected disease, sequence ana-
lysis was performed across putative regulatory regions of
the IFNGR1 gene in 30 Sudanese PKDL patients. Four
novel SNPs (IFNGR1 -77A/G, IFNGR1 + 10C/T, IFNGR1 +
18C/T, and IFNGR1 + 91G/T) located in the upstream
region, exon1, and intron1 of the IFNGR1 gene were iden-
tified. The SNP at +91G/T, along with the previously iden-
tified SNP +95 T/C, are located in/near the splicing site of
the IFNGR1 gene at the intron 1/exon 1 boundary [23].
Alternative alleles at these sites may decrease recognition
of the adjacent exon, consequently preventing splicing out
Figure 1 Graphical representation of the IFNGR1 upstream multiple alignment generated in SynPlot. The sequences of each species are
shown as lines interrupted by spaces corresponding to the gaps inserted for optimum global alignment. The horizontal axis represents the
distance from the start of the alignment, and the vertical axis represents the percentage identity score generated by SynPlot (scale, 0%–100%
sequence identity across all species). Peak regions that correspond to conserved noncoding sequences, as opposed to coding sequences or
repeat features, are numbered. Other features are colour coded according to the key.
Table 3 Known SNPs within CNS peaks identified in the region from the initiation site to 3.5 kb upstream of IFNGR1
SNP Physical position bp CNS peaka Alleles MAFb Loss/gain TFBSc
rs55995532 137541178 3 A/C ---- C/EBbeta
rs17175064 137541195 3 C/A 0.006 -
rs1327473 137541230 3 A/T 0.017 AP-1, C/EBPa1P
rs56273545 137541233 3 A/G ---- -
rs56178591 137541279 3 C/T ---- MAZ, ZNF263
rs17175057 137541297 3 G/A EUR, 0.023 SP1, KLF7
rs17175050 137541521 2 A/T 0.009 NF-1/GATA-1 ZBTB3
aPeaks are numbered in Figure 1. bglobal MAF from SNPDB, −--- indicates no population data available in SNPDB, EUR indicates frequency in PGA European Panel.
MAF, minor allele frequency; cTFBS, transcription factor binding site; grey shading, loss of TFBS; italics, gain of TFBS.
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of this intron and altering the protein sequence and func-
tion. The A to G substitution at nucleotide -77 bp was
also shown to result in loss or gain of the binding site for
the transcription factors CREB and HRE, respectively.
CREB plays a role in cell proliferation, differentiation,
and survival. Once serine 133 of the CREB protein is
phosphorylated. CREB interacts with its co-activator pro-
tein, CREB-binding protein (CBP), to initiate transcription
of CREB-responsive genes [24-26]. A change from A to G
at this position may disrupt this potential binding site, and
thus affect the expression of IFNGR1. The gain of an HRE
might also have important functional consequences. HREs
are hypoxia response elements. Hypoxia promotes blood
vessel formation, and in wounds it promotes the migration
of keratinocytes and restoration of the epithelium [27].
However, none of the novel variants identified in our
study occurred at a frequency in PKDL patients likely to
contribute to the previously observed genetic associations,
and the +91G/T was not in linkage disequilibrium with
markers previously shown to be on risk and protective
haplotypes. Therefore, whilst of interest as potential func-
tional rare variants in this Sudanese population in gen-
eral, the particular SNPs identified here were unlikely
to be major contributors to PKDL susceptibility.
Given the growing interest in the role that rare variants
in orphan diseases can play in translation of genetic
research [28], our study makes an important general
contribution to knowledge of population variants of
potential relevance to Sudan.
The present study also highlighted a cluster of up-
stream CNSs likely to contain the regulatory elements
influencing IFNGR1 expression. In particular, carriage
of alternative alleles at rs55995532, rs1327473, and
rs17175050, rs56178591, rs17175057 result in loss or gain
of transcription factors C/EBPbeta, AP-1, NF-1/GATA-1/
ZBTB3, MAZ/ ZNF263, and SP1/ KLF7, respectively.
Again these polymorphisms are unlikely to be of direct
importance to PKDL in this community, although geno-
typing is required to establish their frequency in this
population. Certainly there is potential for functional im-
portance of these SNPs in relation to immune responses.
For example, the CEBPbeta transcription factor is import-
ant in the regulation of genes involved in immune and in-
flammatory responses and has been shown to bind to the
interleukin (IL)-1 response element in the IL-6 gene, as
well as to regulatory regions of several acute-phase and
cytokine genes [29-32]. Therefore, it will be important to
test whether these polymorphisms are associated with
PKDL and/or in linkage disequilibrium with the IFNGR1
rs141836145 (−270 T/C) SNP or other variants shown to
be on risk versus protective haplotypes previously found
to be associated with PKDL [7].
Figure 2 Cytokine expression relative to the endogenous housekeeping gene β-actin in RNA from lymph node aspirates and skin
biopsies from VL and PKDL patients. (A) and (B) show IFNG and IFNGR1 expression, respectively, in paired lymph node aspirates taken
pre- and post-treatment from 24 VL cases. P values for comparison of pre- and post-treatment samples are based on nonparametric Wilcoxon
matched pairs signed-rank test. (C) shows IFNG and IFNGR1 expression in skin biopsies from 19 PKDL patients. Levels of the two cytokines relative
to β-actin in commercially acquired normal skin (IFNG-NS and IFNGR1-NS) are shown by the horizontal bars.
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IFNG mediates host protection against leishmaniasis,
exerting its pleotropic effect in macrophage activation
and killing Leishmania parasites through induction of ni-
tric oxide [33]. A previous report on mRNA transcripts in
a single patient with PKDL documented strong expression
of both Th1 and Th2 cytokines and the absence or un-
detectable expression of these cytokines in normal skin bi-
opsy samples [34]. In the present study the level of IFNG
expression in PKDL patients was undetectable, as it was
in the control commercially acquired skin sample. This is
in contrast to PKDL in India where elevated expression of
intra-lesional IFNG compared to control skin tissue was
previously observed [35]. Elevated levels of intra-lesional
IFNG mRNA have also been demonstrated in non-healing
patients with CL compared to early lesions [36]. These
results suggest that, in contrast to Indian PKDL and non-
healing CL, the failure of macrophages to become acti-
vated during Sudanese PKDL may be due to the absence
of an intra-lesional Th1-type response. Of interest we
found that mRNA for IFNGR1, although detectable in
some patients, was also uniformly low in all Sudanese
PKDL biopsies relative to the endogenous housekeeper
gene beta-actin. Ansari and colleagues [35] also observed
minimal intra-lesional IFNGR1 expression in Indian
PKDL [35]. This suggests that low or variable expression
of IFNGR1, rather than presence or absence of IFNG per
se, could be the common feature of PKDL across the
geographical and clinical phenotypic divides of India and
Sudan. It is possible that this low IFNGR1 expression level
may lead to a gap in downstream signaling. Almost all cell
types express IFNGR1, but it is of particular importance
to the macrophage, which requires IFNG for control of
intracellular parasites, such as Leishmania. In our pre-
vious studies, PKDL development was shown to be
associated with IFNGR1 polymorphisms [6,7]. The detec-
tion here of a number of regulatory elements within
the novel polymorphisms and CNSs may influence
IFNGR1 expression.
PKDL is an unusual dermatosis that develops in more
than 50% of apparently cured VL cases in Sudan [37,38].
So far, little is known about the parasite/host factors that
drive the parasite to shift from the site of infection to
the dermis. Inadequate treatment is considered to be a
factor in PKDL development. However the disease may
develop even after complete treatment. To study whether
PKDL is influenced by low expression of IFNGR1, changes
in IFNG and IFNGR1 levels upon treatment were analysed
in 24 VL patients. Our results showed that, whilst highly
variable between individuals, the level of IFNG expression
in lymph nodes aspirates from VL patients was signifi-
cantly higher in paired pre-treatment compared to post-
treatment samples. The results are in agreement with
observations regarding increased levels of mRNA encod-
ing IFNG in bone marrow aspirates and lymph nodes
from African patients compared to endemic and U.S. con-
trol groups [39]. High levels of IFNG are also observed in
Leishmania antigen-stimulated whole blood from VL pa-
tients in India [40,41], although this response is lost in
preparation of PBMCs from the same patients consistent
with low levels of IFNG observed in stimulated PBMCs
from studies of other populations [42,43]. This loss of
IFNG response between whole blood and PBMC may be
due to loss of some factor (which has a positive effect on
IFNG production in active VL) during the preparation of
PBMC, and/or to the loss of a specific CD4 T cell popula-
tion during PBMC preparation [40]. We and others
[34,39,40,44] suggest that, during active visceral leishman-
iasis, the immune system is not suppressed but is highly
activated.
The alpha chain encoded by the IFNGR1 gene is the
IFNG binding subunit while the signal transduction sub-
unit is the beta chain. The importance of the alpha chain
for IFNG responsiveness has already been studied. For
example, it has been shown that intra-dermal injection of
even very low numbers of infective L. major promastigotes
in mice knocked-out for the Ifngr1 gene on a genetically
resistant mouse background induced disseminated fatal
disease despite mounting a Th1 response in these mice
[45]. In this study, we found that the expression level of
IFNGR1 mRNA in active VL was highly variable between
individuals, and unchanged pre- and post-treatment in
paired samples. This variability may relate to observa-
tions made by other groups. Kariminia and coworkers
[46] showed that Leishmania infection induces down-
regulation of IFNGR1 on CD45+ cells of the draining
lymph nodes. Another report has demonstrated down
regulation of IFNGR1 in PBMC from VL cases as well as
in the THP1 monocytic cell line infected with Leishmania
[47]. Low expression of IFNGR1 in some VL cases could
provide an indicator of those individuals likely to progress
to PKDL following drug-cure.
Conclusions
Most important amongst our findings was the uniformly
low expression of IFNGR1 in PKDL skin biopsies from
Sudanese patients, which now provides commonality with
Indian PKDL. This could explain parasite persistence and is
consistent with prior demonstration of genetic association
of PKDL with IFNGR1 promoter polymorphisms. Further
work is required to determine whether the additional puta-
tive functional variants in highly conserved regions in the
promoter and upstream regions identified here contribute
to this association. The identification of novel potentially
functional rare variants in the IFNGR1 promoter in this
Sudanese population, whilst unlikely to contribute directly
to risk and protective haplotypes for PKDL, make an im-
portant general contribution to knowledge of rare variants
of potential relevance in this Sudanese population.
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